Trials / Completed
CompletedNCT05218915
Basal Plus GLP1-ra on Glycemic Variability in CKD
Effect of Glucagon-like Peptide 1 Receptor Agonist in Combination with Insulin on Glycaemic Variability and Time-in-range in Diabetic Kidney Disease: a Randomised Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- Elaine Chow · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To compare GLP-1 RA plus basal insulin (BGLP) versus basal-bolus (BB) insulin regimens on glycemic variability (GV) and time in range (TIR) in diabetes patients CKD stage 3-4
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dulaglutide | Dulaglutide once weekly subcutaneous |
| DRUG | Insulin Degludec | Insulin degludec once daily |
| DEVICE | Continuous glucose monitor | Dexcom G6 CGM system |
Timeline
- Start date
- 2022-01-28
- Primary completion
- 2024-10-30
- Completion
- 2024-10-30
- First posted
- 2022-02-01
- Last updated
- 2024-12-03
Locations
1 site across 1 country: Hong Kong
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05218915. Inclusion in this directory is not an endorsement.